NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
Tesaro, Inc.
pharmaand GmbH
Yale University
Bristol-Myers Squibb
University of Alabama at Birmingham
Valerio Therapeutics
Bayer